Adverse reactions to topical ocular autonomic agents.
D001285:Atropine / Q000009:adverse effects; D001337:Autonomic Agents / Q000009:adverse effects*; D003316:Corneal Diseases / Q000139:chemically induced; D003519:Cyclopentolate / Q000009:adverse effects; D004342:Drug Hypersensitivity / Q000209:etiology; D005901:Glaucoma / Q000139:chemically induced / Q000188:drug therapy; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D008916:Miotics / Q000009:adverse effects; D013948:Moxisylyte / Q000009:adverse effects; D009184:Mydriatics / Q000009:adverse effects; D009883:Ophthalmic Solutions / Q000009:adverse effects*; D010656:Phenylephrine / Q000009:adverse effects; D010862:Pilocarpine / Q000009:adverse effects; D011725:Pyridines / Q000009:adverse effects; D013575:Syncope / Q000139:chemically induced
D001337:Autonomic Agents; D008916:Miotics; D009184:Mydriatics; D009883:Ophthalmic Solutions; D011725:Pyridines; D010862:Pilocarpine; D010656:Phenylephrine; D001285:Atropine; D003519:Cyclopentolate; D013948:Moxisylyte